FDA approves Janssen Biotech's STELARA for Crohn’s disease
The US Food and Drug Administration (FDA) has approved Janssen Biotech's STELARA (ustekinumab) to treat moderately to severely active Crohn’s disease in adults (18 years or older) who have failed or were intolerant to treatment with immunomodulators or corticosteroids but never failed treatment with a tumor necrosis factor (TNF) blocker, or who failed or were intolerant to treatment with one or more TNF blockers.
Click on this link for more information.
